Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIC Allo-BMT with PTCy for Refractory Systemic Sclerosis
NCT05298358Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cyclophosphamide in systemic sclerosis (SSc), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Acute Graft vs Host disease (GVHD) incidence at 1 year, Chronic Graft vs Host disease (GVHD) incidence at 1 year and 2 more. Started Nov 2022; status: terminated.
02
Drugs
cyclophosphamide
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT05298358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298358.